1 July 2016

SQS win 22m worth of orders

Ben Jaglom

German software testing concern SQS Software Quality Systems (SQS) has announced a raft of contract wins worth a total of 22 million.

The AIM-quoted concern declared the contract wins will be coming with a deal to provide 'test management, automation and functional testing' to a 'large European logistics company' This contract is said to be worth 10 million over the next two years. Another deal is to provide the same services but to the French operations of a 'global insurance provider' worth 5 million. Its other contracts include wins with 'four leading retail companies' worth a total of 3.3 million, three public sector contracts worth 2.5 million, a contract with a 'multi-national media company' worth 500,000 and a deal with a 'major UK utilities company' costing €300,000.

SQS' chief executive officer Rudolf van Megen enthused that the win 'highlight the compelling value propositions' of SQS' products and services adding that it provides the company with confidence for the expansion of our regional presence and market share.'

Analysts at house broker Arbuthnot held their forecasts. The broker expects pre-tax profits of 11.4 million (EPS: 28.96 cents) on sales of 178.7 million for the year to December 2011. In 2012 it predicts profits of 13.6 million (EPS: 33.6 cents) on revenue of 199.6 million.

Growth Company Investor recommended shares in SQS this January as a buy/hold at 225p and they have since lost 11.3 per cent, currently trading at 199.5p. Though the latest wins have not moved forecasts they are nonetheless encouraging steps. We retain our buy/hold rating.

Tags: Business in Germany, German Technology, Independent software testing, Quality management services

Cash Shells 2015

Published in September 2015 this annual research report provides a comprehensive overview of cash shells on the Main Market, AIM and PLUS landscape. Order your copy today

 

Superb investment toolkit for private investors

SharePad is the new web-based service from ShareScope. Easier to use and more powerful. Perfect for tablets, Macs and Windows PC. Covers ALL your investment requirements.

Growth Company Investor: free trial

Since 2008, our share tips outperformed the benchmark by 281%. Take a free trial and get access to our recommendations today. Start free trial now.

Directors' Pay on AIM 2015

The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info

 

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

The robots are coming

Recent AIM newcomer Blue Prism (AIM: PRSM) has released a promising set of maiden results for the half year to April. Revenues grew by a handy 21 per cent and momentum seems to be accelerating with 33 new customers added to the 57 in place at the end of October. 

Avingtrans returns cash and remains a Buy

Having turned most of its market cap into cash through the sale of its aerospace division, it’s no surprise that Avingtrans (AIM: AVG) has been a very defensive stock during the recent turmoil. We now have some more details on the return of cash to shareholders which was promised as part of the disposal.

Omega investing in growth

Omega Diagnostics results looked positive and highlighted the progress being made in getting important new products to market. The investment to support those efforts will depress profits this year; but the market seems willing to look through this with Omega being a rare stock to be trading above its pre-Brexit level.

Stadium hit by profit warning

Stadium Group shares have been hit by a profit warning. This is a particular blow given the company’s progress in repositioning itself into a higher quality, design-led business.

Verona raises £42m to fund drug trials 

Verona Pharma (AIM: VRP) has raised an impressive £42 million net of costs which will fund phase II trials for its RPL554 compound. This drug targets severe respiratory diseases, in particular the 65 million worldwide sufferers from COPD (chronic obstructive pulmonary disease).

Income attractions at Belvoir

It’s fair to say that buy-to-let landlords have been under George Osborne’s cosh. He’s introduced a raised stamp duty rate and withdrawn higher-rate tax relief. However, Belvoir Lettings has seen little change in the market as far as its core lettings agency business is concerned. Furthermore, the shares have responded positively to a major acquisition which makes Belvoir the largest UK lettings agent.

More News